All Resources

Using a sample pediatric case study (Rosa), this video describes how autoantibody screening can enable early detection of presymptomatic T1D, providing a window of opportunity to prepare for clinical diagnosis

People identified early through screening programs have milder disease and better quality of life compared to control

Explore the association of GWAS and GRS and how they can improve T1D

GRS helps to select individuals at high risk for T1D for screening

T1D has three different stages, characterized by increasing loss of beta-cell function

CD8+ T cell exhaustion rate predicts progression of T1D

People positive for at least one islet autoantibody should be monitored regularly

The number, type, and titer of islet autoantibodies detected in T1D screening tests provide valuable information about potential progression to clinical T1D. 

Explore how clinical outcomes are impacted by screening and monitoring

Overview of the factors playing a role in the etiology of T1D.

A guide to autoimmune type 1 diabetes (T1D) screening tests.

At the BR1DGE symposium at IDS 2024, leading experts shared new insights on the mechanisms driving autoimmune type 1 diabetes (T1D), emphasizing the benefits of genetic risk scoring, and the latest biomarker research.  

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.